The last couple of years have been tough for Bayer AG and its investors, many of whom will be nonplussed by plans to slash its dividend by 95% as the conglomerate looks to bring down its vast debts built up from the ill-fated acquisition of Monsanto in 2018.
Bayer Cuts Dividend To The Bone To Cut Debt
The embattled German major is touting a promising mid-stage thrombolytic but the spotlight this week has continued to shine on its business model and high levels of debt.
More from Strategy
More from Business
• By
The US FDA approved anti-CD19 antibody Uplizna, from Amgen’s $27.8bn purchase of Horizon in 2023, for IgG4-related disease – a larger market than its original NMOSD indication.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.